Loss of CHGA Protein as a Potential Biomarker for Colon Cancer Diagnosis: A Study on Biomarker Discovery by Machine Learning and Confirmation by Immunohistochemistry in Colorectal Cancer Tissue Microarrays
Source check: Source checked. Not independent scientific confirmation.
Finding: Machine-learning screening of protein-interaction candidates selected CHGA as a colorectal-cancer biomarker; the study reports AUC 0.90 in microarray data, 0.995 in RNA-seq data and immunohistochemistry across 198 specimens. This supports a candidate biomarker association, not prospective screening benefit.
Technology: Machine learning screens protein-interaction candidates; CHGA is selected and evaluated in tissue arrays.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Machine learning screens protein-interaction candidates; CHGA is selected and evaluated in tissue arrays.
- Test and result
- Results reports AUC 0.90 microarray, 0.995 RNA-seq and IHC across 198 specimens; follow-up is candidate biomarker evidence.
- Limitation / still unknown
- Evidence supports a candidate biomarker association; prospective screening and clinical outcomes were not tested.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://europepmc.org/articles/PMC9179857 · https://pubmed.ncbi.nlm.nih.gov/35681650/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.